Antiemetic control: 5-HT3 antagonists: Review of clinical results, with particular emphasis on ondansetron
- 30 September 1990
- journal article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 17 (2-3) , 311-317
- https://doi.org/10.1016/0305-7372(90)90063-l
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- The effect of three dose levels of ICS 205–930 (a selective 5HT-3 antagonist) on cisplatin-induced nausea and vomitingEuropean Journal of Cancer and Clinical Oncology, 1989
- New benzamide anti-emeticsDrugs of the Future, 1989
- PREVENTION OF EMESIS IN PATIENTS RECEIVING CYTOTOXIC DRUGS BY GR38032F, A SELECTIVE 5-HT3 RECEPTOR ANTAGONISTThe Lancet, 1987
- FIRST RESULTS WITH ICS 205-930 (5-HT3 RECEPTOR ANTAGONIST) IN PREVENTION OF CHEMOTHERAPY-INDUCED EMESISThe Lancet, 1987